Eli Lilly's Phase 3b TOGETHER-PsO trial revealed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader changes in psoriasis and metabolic biomarkers compared to Taltz alone as early as Week 12. This suggests a linked immune-metabolic relationship in patients with moderate-to-severe plaque psoriasis and obesity, a group where 61% have related comorbidities. The combo also showed superior skin clearance and weight reduction at Week 36, supporting a more integrated treatment approach addressing both psoriasis and obesity. Further research is encouraged to explore this immunometabolic connection.
As of Oct 09, 2026 17:51 WIB, Eli Lilly And Co (LLY) shares are priced at USD 1,164.15 on Pluang, with a slight 0.49% decrease over the past day. The stock shows a strong buy interest with 69% of orders favoring purchases and a typical hold time of 93 days. Eli Lilly's market cap stands at $1.04 trillion, highlighting its significant presence in the health sector amid ongoing research advances like the TOGETHER-PsO trial.
Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Mor...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
